Effectiveness of the 10-valent pneumococcal conjugate vaccine on pediatric pneumonia confirmed by ultrasound: a matched case-control study.
Child health
Pneumococcal conjugate vaccine
Pneumonia
South Asia
Ultrasound
Vaccine effectiveness
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
01 Aug 2022
01 Aug 2022
Historique:
received:
15
04
2022
accepted:
05
07
2022
entrez:
1
8
2022
pubmed:
2
8
2022
medline:
4
8
2022
Statut:
epublish
Résumé
Bangladesh introduced the 10-valent pneumococcal conjugate vaccine (PCV10) for children aged < 1 year in March 2015. Previous vaccine effectiveness (VE) studies for pneumonia have used invasive pneumococcal disease or chest X-rays. None have used ultrasound. We sought to determine the VE of PCV10 against sonographically-confirmed pneumonia in three subdistrict health complexes in Bangladesh. We conducted a matched case-control study between July 2015 and September 2017 in three subdistricts of Sylhet, Bangladesh. Cases were vaccine-eligible children aged 3-35 months with sonographically-confirmed pneumonia, who were matched with two types of controls by age, sex, week of diagnosis, subdistrict health complex (clinic controls) or distance from subdistrict health complex (community controls) and had an illness unlikely due to Streptococcus pneumoniae (clinic controls) or were healthy (community controls). VE was measured using multivariable conditional logistic regression. We evaluated 8926 children (average age 13.3 months, 58% boys) with clinical pneumonia by ultrasound; 2470 had pneumonia with consolidations ≥ 1 cm; 1893 pneumonia cases were matched with 4238 clinic controls; and 1832 were matched with 3636 community controls. VE increased with the threshold used for consolidation size on ultrasound: the adjusted VE of ≥ 2 doses vs. non-recipients of PCV10 against pneumonia increased from 15.8% (95% CI 1.6-28.0%) for consolidations ≥ 1 cm to 29.6% (12.8-43.2%) for consolidations ≥ 1.5 cm using clinic controls and from 2.7% (- 14.2-17.2%) to 23.5% (4.4-38.8%) using community controls, respectively. PCV10 was effective at reducing sonographically-confirmed pneumonia in children aged 3-35 months of age when compared to unvaccinated children. VE increased with the threshold used for consolidation size on ultrasound in clinic and community controls alike. This study provides evidence that lung ultrasound is a useful alternative to chest X-ray for case-control studies evaluating the effectiveness of vaccines against pneumonia.
Sections du résumé
BACKGROUND
BACKGROUND
Bangladesh introduced the 10-valent pneumococcal conjugate vaccine (PCV10) for children aged < 1 year in March 2015. Previous vaccine effectiveness (VE) studies for pneumonia have used invasive pneumococcal disease or chest X-rays. None have used ultrasound. We sought to determine the VE of PCV10 against sonographically-confirmed pneumonia in three subdistrict health complexes in Bangladesh.
METHODS
METHODS
We conducted a matched case-control study between July 2015 and September 2017 in three subdistricts of Sylhet, Bangladesh. Cases were vaccine-eligible children aged 3-35 months with sonographically-confirmed pneumonia, who were matched with two types of controls by age, sex, week of diagnosis, subdistrict health complex (clinic controls) or distance from subdistrict health complex (community controls) and had an illness unlikely due to Streptococcus pneumoniae (clinic controls) or were healthy (community controls). VE was measured using multivariable conditional logistic regression.
RESULTS
RESULTS
We evaluated 8926 children (average age 13.3 months, 58% boys) with clinical pneumonia by ultrasound; 2470 had pneumonia with consolidations ≥ 1 cm; 1893 pneumonia cases were matched with 4238 clinic controls; and 1832 were matched with 3636 community controls. VE increased with the threshold used for consolidation size on ultrasound: the adjusted VE of ≥ 2 doses vs. non-recipients of PCV10 against pneumonia increased from 15.8% (95% CI 1.6-28.0%) for consolidations ≥ 1 cm to 29.6% (12.8-43.2%) for consolidations ≥ 1.5 cm using clinic controls and from 2.7% (- 14.2-17.2%) to 23.5% (4.4-38.8%) using community controls, respectively.
CONCLUSIONS
CONCLUSIONS
PCV10 was effective at reducing sonographically-confirmed pneumonia in children aged 3-35 months of age when compared to unvaccinated children. VE increased with the threshold used for consolidation size on ultrasound in clinic and community controls alike. This study provides evidence that lung ultrasound is a useful alternative to chest X-ray for case-control studies evaluating the effectiveness of vaccines against pneumonia.
Identifiants
pubmed: 35915495
doi: 10.1186/s12931-022-02115-5
pii: 10.1186/s12931-022-02115-5
pmc: PMC9341060
doi:
Substances chimiques
10-valent pneumococcal conjugate vaccine
0
Pneumococcal Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
198Subventions
Organisme : Bill & Melinda Gates Foundation
ID : OPP1084286
Pays : United States
Organisme : Bill & Melinda Gates Foundation
ID : OPP1117483
Pays : United States
Organisme : GlaxoSmithKline
ID : 90063241
Informations de copyright
© 2022. The Author(s).
Références
Gates Open Res. 2018 Apr 26;2:21
pubmed: 29984359
Chest. 2008 Jul;134(1):117-25
pubmed: 18403664
Chest. 2016 Jul;150(1):131-8
pubmed: 26923626
Lancet. 2019 Aug 31;394(10200):757-779
pubmed: 31257127
Am J Respir Crit Care Med. 2019 Mar 15;199(6):701-714
pubmed: 30372119
Lancet Glob Health. 2018 Jul;6(7):e744-e757
pubmed: 29903376
Thorax. 2015 Dec;70(12):1149-55
pubmed: 26092924
N Engl J Med. 2003 Oct 2;349(14):1341-8
pubmed: 14523142
BMC Pulm Med. 2018 Dec 7;18(1):191
pubmed: 30526548
Pediatrics. 2015 Apr;135(4):714-22
pubmed: 25780071
Pediatr Pulmonol. 2019 Nov;54(11):1753-1759
pubmed: 31432618
Bull World Health Organ. 2008 May;86(5):365-72
pubmed: 18545739
Respir Med. 2017 Jul;128:57-64
pubmed: 28610670
Vaccine. 2020 Sep 29;38(42):6508-6516
pubmed: 32873404
Pediatr Infect Dis J. 2006 Sep;25(9):779-81
pubmed: 16940833
Chest. 2018 Dec;154(6):1385-1394
pubmed: 30291926
Lancet Respir Med. 2019 Dec;7(12):1068-1083
pubmed: 31591066
Lancet. 2007 Oct 20;370(9596):1453-7
pubmed: 18064739
Pediatr Infect Dis J. 2009 Jun;28(6):455-62
pubmed: 19483514
Vaccine. 2016 Aug 17;34(37):4371-7
pubmed: 27443591
Sci Rep. 2019 Nov 29;9(1):17957
pubmed: 31784642
Lancet. 2017 Dec 17;388(10063):3027-3035
pubmed: 27839855
Bull World Health Organ. 2005 May;83(5):353-9
pubmed: 15976876
Lancet. 2005 Mar 26-Apr 1;365(9465):1139-46
pubmed: 15794968
Vaccine. 2017 Jun 5;35(25):3303-3308
pubmed: 28442230
Clin Infect Dis. 2021 Dec 6;73(11):e3788-e3796
pubmed: 32710751
Pediatr Infect Dis J. 2014 Jan;33 Suppl 2:S119-29
pubmed: 24336054
Lancet Infect Dis. 2017 Sep;17(9):965-973
pubmed: 28601421